November 24, 2016 - By Louis Casey
An insider of the company Masimo Corp, Joe Kiani also its CEO and Chairman of the Board, disclosed his trade activities with the U.S. Security and Exchange Commission on November 23, 2016. As revealed in the document, Joe had unloaded 85,771 shares of the California-based Masimo Corp. The total sale was worth $5,323,312 USD. At the time of the trade the price of a share was $62.1. In the last 30 days, he also sold 20,381 shares worth approximately $1,263,959 USD. Being a significant stocks unloading, it will most likely not go hidden. Joe Kiani now has 6.11% of Masimo Corp’s market cap with ownership of 3.05 million shares.
Out of 3 analysts covering Masimo (NASDAQ:MASI), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $51 is the highest target while $46 is the lowest. The $48.50 average target is -21.89% below today’s ($62.09) stock price. Masimo has been the topic of 3 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock of Masimo Corporation (NASDAQ:MASI) has “Buy” rating given on Wednesday, August 5 by TH Capital. The firm earned “Outperform” rating on Wednesday, January 6 by Raymond James.
Insitutional Activity: The institutional sentiment increased to 1.33 in Q2 2016. Its up 0.01, from 1.32 in 2016Q1. The ratio is positive, as 14 funds sold all Masimo Corporation shares owned while 85 reduced positions. 52 funds bought stakes while 79 increased positions. They now own 38.69 million shares or 0.37% less from 38.84 million shares in 2016Q1.
Renaissance Tech Limited Liability Corporation has 143,800 shares for 0.01% of their US portfolio. Paloma Ptnrs Mgmt Com owns 76,526 shares or 0.04% of their US portfolio. Bnp Paribas Investment Ptnrs holds 0.11% or 251,225 shares in its portfolio. Tower Capital Ltd Liability (Trc) has 2,204 shares for 0.01% of their US portfolio. Capital Impact has 23,427 shares for 0.58% of their US portfolio. Moreover, Acadian Asset Mngmt Lc has 0.03% invested in Masimo Corporation (NASDAQ:MASI) for 122,818 shares. Moreover, Barclays Public Limited Co has 0% invested in Masimo Corporation (NASDAQ:MASI) for 62,580 shares. Dimensional Fund Advsrs Lp has 0.03% invested in the company for 1.13 million shares. Price T Rowe Md has 466,280 shares for 0.01% of their US portfolio. Janus Cap Management Ltd Liability Com accumulated 2.78M shares or 0.12% of the stock. Public Sector Pension Inv Board, a Quebec – Canada-based fund reported 31,628 shares. The Florida-based Raymond James Fincl Ser Advsrs has invested 0% in Masimo Corporation (NASDAQ:MASI). Moreover, Highbridge Capital Mgmt Ltd Liability Company has 0.03% invested in Masimo Corporation (NASDAQ:MASI) for 35,086 shares. Paradigm Asset Management Co Ltd Liability Co last reported 2,500 shares in the company. Manufacturers Life The holds 0% or 27,819 shares in its portfolio.
Insider Transactions: Since May 25, 2016, the stock had 0 insider purchases, and 27 selling transactions for $33.69 million net activity. 2,000 shares were sold by FITCH SANFORD, worth $119,167 on Wednesday, October 5. KIANI JOE E sold $267,877 worth of stock. 4,000 shares were sold by Coleman Jon, worth $200,000. $1.18 million worth of Masimo Corporation (NASDAQ:MASI) was sold by Fishel Rick. 65,000 shares were sold by Sampath Anand, worth $3.58 million. Another trade for 5,000 shares valued at $262,500 was sold by Van Ramshorst David J. $1.82 million worth of Masimo Corporation (NASDAQ:MASI) was sold by Lee Yongsam on Monday, October 10.
The stock increased 0.50% or $0.31 during the last trading session, hitting $62.09. About 229,396 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 43.57% since April 21, 2016 and is uptrending. It has outperformed by 38.25% the S&P500.
Masimo Corporation is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The company has a market cap of $3.07 billion. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology pulse oximetry. It has a 29.94 P/E ratio. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
According to Zacks Investment Research, “Masimo develops innovative monitoring technologies that significantly improve patient care — helping solve unsolvable problems. The company debuted Read-Through Motion and Low Perfusion pulse oximetry, known as SET, and with it substantially reduced false alarms and increased pulse oximetry’s ability to detect life-threatening events. Our Masimo SET platform has significantly addressed many of the previous technology limitations, has substantially contributed to improved patient outcomes and has been referred to by several industry sources as the gold standard in pulse oximetry. Masimo has introduced Masimo Rainbow SET Pulse CO-Oximetry, which, for the first time, noninvasively monitors the level of carbon monoxide and methemoglobin in the blood, allowing early detection and treatment of potentially life-threatening conditions. Masimo has the mission of Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications.”
Analysts await Masimo Corporation (NASDAQ:MASI) to report earnings on February, 28. They expect $0.51 EPS, up 240.00% or $0.36 from last year’s $0.15 per share. MASI’s profit will be $25.22 million for 30.44 P/E if the $0.51 EPS becomes a reality. After $0.47 actual EPS reported by Masimo Corporation for the previous quarter, Wall Street now forecasts 8.51% EPS growth.
Masimo Corporation, incorporated on May 7, 1996, is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring. In addition, the Company has developed the Root patient monitoring and connectivity platform, the Radical-7 bedside and portable patient monitor and the Radius-7 wearable wireless patient monitor. It has also developed the Patient SafetyNet remote patient surveillance monitoring system, which allows over 200 patients to be monitored simultaneously and remotely through a personal computer (PC) viewing station or by care providers through their pagers, voice-over-Internet Protocol (IP) phones or smartphones.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey